Skip to main content
OpenTrials
Completed

NCT Number: NCT06992479

Efficacy of HFNC Combined With Sequential NIV in Patients With COPD Complicated With Type II Respiratory Failure

The goal of this clinical trial is to investigate the efficacy of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV) in patients with chronic obstructive pulmonary disease complicated with type II respiratory failure. The main questions it aims to answer are:

What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on arterial blood gas indicators in patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on pulmonary ventilation function in patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on vital signs in patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on the quality of life of patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on complications in patients with chronic obstructive pulmonary disease and type II respiratory failure?

Participants will:

Receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital Receive other standard treatments according to the latest GOLD guidelines The general data of patients, arterial blood gas index, pulmonary ventilation function, vital signs index, quality of life and complications before and after treatment were collected.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease (COPD) Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Nasal High Flow Oxygen Therapy Noninvasive Ventilation Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiration Disorders Respiratory Failure Respiratory Insufficiency Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing You'an Hospital, Capital Medical University

Beijing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All subjects included in the study met the diagnostic criteria for AECOPD in the Global Initiative for Chronic Obstructive Pulmonary Disease (2014 Update);
  • Age > 18 years old;
  • All patients met the diagnostic criteria for type II respiratory failure in the eighth edition of ' Internal Medicine ', that was, arterial blood PaO2 < 50mmHg;
  • The patient was conscious, without myocardial infarction, acute stroke, severe liver and kidney dysfunction, severe coagulation dysfunction and other diseases;
  • The patient did not have life-threatening hypoxemia and severe hemodynamic instability, and did not need tracheal intubation or tracheotomy;
  • Patients can cooperate with pulmonary function tests.

Exclusion criteria

  • Patients with pneumothorax, mediastinal emphysema or severe thoracic deformity;
  • Patients with bronchial asthma, interstitial pneumonia and other diseases;
  • Patients with coma and disturbance of consciousness;
  • The upper respiratory tract or facial injury and facial deformity, can not wear a good nose (face) mask;
  • Patients with septic shock or severe heart, kidney, liver and other diseases;
  • Sputum and sticky, unable to expectoration or prone to aspiration caused by airway obstruction.
  • Automatic discharge or transfer, or due to non-respiratory serious diseases (including non-invasive ventilator complications, non-invasive ventilation treatment ineffective need to be changed to invasive ventilation), termination of the study patients.

Treatment and study plan

high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV)

Device

The control group was treated with NIV routine treatment. During non-invasive ventilation, patients in both the intervention group and the conventional group will receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital. Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 ~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 ~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.

The study group was treated with nasal high-flow oxygen therapy combined with sequential non-invasive ventilation. Patients will receive high-flow oxygen therapy ventilator during the day and in the morning and evening awake time (manufacturer: Hunan Mingkang Zhongjin Medical Technology Co., Ltd., registration number: Xiangji Zhuzhun 20192080049, model: OH60A) treatment. At night (from 10 p.m. to 6

NIV routine treatment

Device

Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 ~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 ~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.

Primary outcomes

  1. arterial blood gas indexes

    Time frame: before and after 7 days of BiPAP treatment

  2. the first second forced expiratory volume

    Time frame: before and after 7 days of BiPAP treatment

  3. forced vital capacity

    Time frame: before and after 7 days of BiPAP treatment

  4. FEV1 / FVC

    Time frame: before and after 7 days of BiPAP treatment

  5. FEV1 / predicted value

    Time frame: before and after 7 days of BiPAP treatment

  6. PEF / predicted value

    Time frame: before and after 7 days of BiPAP treatment

  7. heart rate

    Time frame: before and after 7 days of BiPAP treatment

  8. respiratory rate

    Time frame: before and after 7 days of BiPAP treatment

  9. blood pressure

    Time frame: before and after 7 days of BiPAP treatment

  10. Quality of life

    Time frame: before and after 7 days of BiPAP treatment

    SF-36 comprehensively summarized the quality of life of respondents from eight aspects: physiological function, physiological function, physical pain, general health status, energy, social function, emotional function and mental health. The score range is 0-100. The higher the score, the better the situation.

  11. Complications

    Time frame: before and after 7 days of BiPAP treatment

Sponsors and collaborators

Lead sponsor

Beijing YouAn Hospital

Other

Registry information

Official study title

Efficacy of Nasal High-flow Oxygen Therapy Combined With Sequential Non-invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Complicated With Type II Respiratory Failure

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
May 28, 2025
Registry last updated
May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.